Journal article
CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Abstract
Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow transplantation was conducted before the importance of CD25+FOXP3+ regulatory T cells (Tregs) was recognized. Tregs can abrogate the onset of GVHD. The relation between Tregs and a graft-versus-malignancy effect is not fully …
Authors
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S
Journal
Transplantation and Cellular Therapy, Vol. 23, No. 3, pp. 405–411
Publisher
Elsevier
Publication Date
3 2017
DOI
10.1016/j.bbmt.2016.12.624
ISSN
2666-6367
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAntibodies, Monoclonal, HumanizedCD4 Lymphocyte CountChildChild, PreschoolDaclizumabDouble-Blind MethodFemaleGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunoglobulin GInfantInterleukin-2 Receptor alpha SubunitMaleMiddle AgedT-Lymphocytes, RegulatoryTransplantation, HomologousYoung Adult